Bioregenx (BRGX) EBIAT (2022 - 2025)
Bioregenx's EBIAT history spans 4 years, with the latest figure at -$1.0 million for Q4 2025.
- Quarterly results put EBIAT at -$1.0 million for Q4 2025, up 94.47% from a year ago — trailing twelve months through Dec 2025 was -$1.5 million (up 93.3% YoY), and the annual figure for FY2025 was -$1.5 million, up 93.3%.
- EBIAT for Q4 2025 was -$1.0 million at Bioregenx, down from -$80565.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$2191.0 in Q3 2022 to a low of -$18.4 million in Q4 2024.
- The 4-year median for EBIAT is -$261801.0 (2023), against an average of -$1.8 million.
- The sharpest move saw EBIAT tumbled 114871.93% in 2023, then soared 94.47% in 2025.
- Year by year, EBIAT stood at -$5535.0 in 2022, then crashed by 4538.63% to -$256748.0 in 2023, then tumbled by 7066.78% to -$18.4 million in 2024, then soared by 94.47% to -$1.0 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$1.0 million, -$80565.0, and -$178345.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.